Biomarkers in Islet Cell Transplantation for Type 1 Diabetes

AlRashidi, Fatimah T.; Gillespie, Kathleen M.

doi:10.1007/s11892-018-1059-4

Cited by 13 publications

(8 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study suggests a correlation among the methylation patterns of cfDNA in recently diagnosed T1D patients, the rate of beta-cell death, and the risk of developing the disease [ 99 ]. In T1D patients with difficulties in controlling their blood glucose levels through insulin management, the replacement of beta-cells (through whole pancreas transplantation or islet transplantation) represents a therapeutic option [ 100 ]. The analysis of methylation in cfDNA from T1D patients after the replacement of beta-cells correlates with clinical outcomes, thus predicting early engraftment [ 101 ].…”

Section: Circulating Free Dna In Other Autoimmune Disordersmentioning

confidence: 99%

Circulating Free DNA and Its Emerging Role in Autoimmune Diseases

Mondelo‐Macía

Castro‐Santos

Castillo‐García³

et al. 2021

JPM

View full text Add to dashboard Cite

Liquid biopsies can be used to analyse tissue-derived information, including cell-free DNA (cfDNA), circulating rare cells, and circulating extracellular vesicles in the blood or other bodily fluids, representing a new way to guide therapeutic decisions in cancer. Among the new challenges of liquid biopsy, we found clinical application in nontumour pathologies, including autoimmune diseases. Since the discovery of the presence of high levels of cfDNA in patients with systemic lupus erythaematosus (SLE) in the 1960s, cfDNA research in autoimmune diseases has mainly focused on the overall quantification of cfDNA and its association with disease activity. However, with technological advancements and the increasing understanding of the role of DNA sensing receptors in inflammation and autoimmunity, interest in cfDNA and autoimmune diseases has not expanded until recently. In this review, we provide an overview of the basic biology of cfDNA in the context of autoimmune diseases as a biomarker of disease activity, progression, and prediction of the treatment response. We discuss and integrate available information about these important aspects.

show abstract

Section: Circulating Free Dna In Other Autoimmune Disordersmentioning

confidence: 99%

Circulating Free DNA and Its Emerging Role in Autoimmune Diseases

Mondelo‐Macía

Castro‐Santos

Castillo‐García³

et al. 2021

JPM

View full text Add to dashboard Cite

show abstract

“…Alloimmunity is controlled by measuring DSA. Pre-transplantation DSA was associated with failure of the transplant, but not all studies have proven this [ 83 ]. A limiting factor in predicting early and long-term function of a transplant is the impossibility of determining cell death after transplantation.…”

Section: Cfdna In Transplantationsmentioning

confidence: 99%

Donor-Derived Cell-Free DNA in Kidney Transplantation as a Potential Rejection Biomarker: A Systematic Literature Review

Martuszewski

Paluszkiewicz

Król

et al. 2021

JCM

View full text Add to dashboard Cite

Kidney transplantation (KTx) is the best treatment method for end-stage kidney disease. KTx improves the patient’s quality of life and prolongs their survival time; however, not all patients benefit fully from the transplantation procedure. For some patients, a problem is the premature loss of graft function due to immunological or non-immunological factors. Circulating cell-free DNA (cfDNA) is degraded deoxyribonucleic acid fragments that are released into the blood and other body fluids. Donor-derived cell-free DNA (dd-cfDNA) is cfDNA that is exogenous to the patient and comes from a transplanted organ. As opposed to an invasive biopsy, dd-cfDNA can be detected by a non-invasive analysis of a sample. The increase in dd-cfDNA concentration occurs even before the creatinine level starts rising, which may enable early diagnosis of transplant injury and adequate treatment to avoid premature graft loss. In this paper, we summarise the latest promising results related to cfDNA in transplant patients.

show abstract

“…The islets of Langerhans are composed of many endocrine cell types that produce various hormones, including a cells (*30%, glucagon), b cells (*60-80%, insulin), d cells (<10%, somatostatin), PP or g cells (<5%, pancreatic polypeptide), and e cells (ghrelin). 73 Nutrient and oxygen delivery are critical to islets in the pancreas, as they are known to be highly metabolically active. Increased oxygen consumption demands and adenosine triphosphate (ATP) production 74 drive 5-20% of the arterial blood flow to the pancreas toward the islets, despite them accounting for only 1-2% of its mass.…”

Section: The Pancreatic Islet Microenvironmentmentioning

confidence: 99%

3D Bioprinting and Translation of Beta Cell Replacement Therapies for Type 1 Diabetes

Gurlin

Giraldo

Latres

2021

Tissue Engineering Part B: Reviews

View full text Add to dashboard Cite

Type 1 diabetes (T1D) is an autoimmune disorder in which the body's own immune system selectively attacks beta cells within pancreatic islets resulting in insufficient insulin production and loss of the ability to regulate blood glucose (BG) levels. Currently, the standard of care consists of BG level monitoring and insulin administration, which are essential to avoid the consequences of dysglycemia and long-term complications. Although recent advances in continuous glucose monitoring and automated insulin delivery systems have resulted in improved clinical outcomes for users, nearly 80% of people with T1D fail to achieve their target hemoglobin A1c (HbA1c) levels defined by the American Diabetes Association. Intraportal islet transplantation into immunosuppressed individuals with T1D suffering from impaired awareness of hypoglycemia has resulted in lower HbA1c, elimination of severe hypoglycemic events, and insulin independence, demonstrating the unique potential of beta cell replacement therapy (BCRT) in providing optimal glycemic control and a functional cure for T1D. BCRTs need to maximize cell engraftment, long-term survival, and function in the absence of immunosuppression to provide meaningful clinical outcomes to all people living with T1D. One innovative technology that could enable widespread translation of this approach into the clinic is three-dimensional (3D) bioprinting. Herein, we review how bioprinting could facilitate translation of BCRTs as well as the current and forthcoming techniques used for bioprinting of a BCRT product. We discuss the strengths and weaknesses of 3D bioprinting in this context in addition to the road ahead for the development of BCRTs.

show abstract

Biomarkers in Islet Cell Transplantation for Type 1 Diabetes

Cited by 13 publications

References 73 publications

Circulating Free DNA and Its Emerging Role in Autoimmune Diseases

Circulating Free DNA and Its Emerging Role in Autoimmune Diseases

Donor-Derived Cell-Free DNA in Kidney Transplantation as a Potential Rejection Biomarker: A Systematic Literature Review

3D Bioprinting and Translation of Beta Cell Replacement Therapies for Type 1 Diabetes

Contact Info

Product

Resources

About